Phase 4 N=2,776 Study of Tomography of Nephrolithiasis Evaluation
Urolithiasis
Primary: High Risk Diagnosis With Complication — 6; 3; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=157 The Study Of Fluconazole For Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Therapeutic Outcome: Response Rate — 33.7; 54.2; 74.7 percentage of participants
Phase 1 N=20 Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.
Epilepsy
Primary: Cmax - Maximum Observed Plasma BIA 2-194 Concentration — 0.00; 8443; 10691; 10961 ng/mL
N/A N=35 Clitoral Location in Relation to Sexual Function Using Pelvic Imaging
Female Sexual Dysfunction · Anorgasmia
Primary: Clitoral Measurements Using Pelvic MRI — 51.3; 45.1; 29.4; 20.6 millimeters (mm)
N/A N=8 Trial on the Effect of Optically Modified Fiber Mattress Covers on Sleep Disturbances in Patients With Chronic Back Pain
Back Pain · Insomnia
Primary: Optically Modified Polyethylene Terephthalate Fiber Mattress Cover (OMPETFMC) Improves Sleep Quality in Patients With Lower Back Pain as Measured by Clinical Global…
Phase 4 N=89 Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.
Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft
Primary: Number of Participants Achieving at Least Two Mycophenolic Acid (MPA) Dose Steps Higher and Reducing Tacrolimus Dose at the End of the Study — 0; 0; 43; 38 number of…
N/A N=446 PEU in Elderly TCU Residents
Aging
Primary: Percentage of Subjects With Average Daily Nutrient Intake <70% of Predicted Needs — 26 percentage of subjects
Phase 2 N=129 Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)
Infertility, Female
Primary: Embryo Implantation and Clinical Pregnancy Rates — 32; 33 Gestational sacs — p=0.72
N/A N=120 Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging
Coronary Disease
Primary: Ability to Detect Stress-induced Myocardial Perfusion Abnormalities by Analysis of MDCT Images Confirmed by Coronary Angiography and/or SPECT. — 78 % accurately detected…
Phase 2 N=105 A Trial of Rosiglitazone for Ulcerative Colitis
Ulcerative Colitis · Inflammatory Bowel Disease
Primary: Number of Participants With Improvement of Signs and Symptoms of UC at 12 Weeks — 23; 12 participants — p=.005
Phase 4 N=16 Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa
Pompe Disease (Late-Onset) · Glycogen Storage Disease Type II (GSD II) · Glycogenesis 2 Acid Maltase Deficiency
Primary: Change From Baseline in Tissue Glycogen Content in Quadriceps Muscle Biopsy Samples at Week 26 — 5.3; -1.6 percent area occupied by glycogen — p=0.1860
Phase 3 N=54 Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
Epilepsies, Partial
Primary: Number of Participants With Adverse Events (AE). — 14; 13; 11; 9 Participants
Phase 3 N=1,359 Induction of Mild Hypothermia Following Out-of-hospital Cardiac Arrest
Out-of-hospital Cardiac Arrest
Primary: Number Alive at Hospital Discharge — 187; 183; 62; 76 participants
Phase 3 N=565 Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)
Infection; Diabetic Foot
Primary: Percentage of Participants With Favorable Clinical Response Assessments at Discontinuation of Intravenous (IV) Study Therapy (DCIV) — 93.6; 97.3 Percentage of participants
Phase 1 N=41 A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120
Neoplasms
Primary: Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1 — 100; 0; 0; 11 percentage of participants